Synthetic ghrelin - Oxeia Biopharmaceuticals

Drug Profile

Synthetic ghrelin - Oxeia Biopharmaceuticals

Alternative Names: OXE-103; SUN 11031 - KineMed

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biopharma Forest; University of California, San Diego
  • Developer KineMed; Oxeia Biopharmaceuticals
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries
  • Discontinued Muscular atrophy

Most Recent Events

  • 02 Aug 2017 Oxeia Biopharmaceuticals plans phase II studies for Brain injuries in early 2018
  • 02 Aug 2017 Synthetic ghrelin licensed to Oxeia Biopharmaceuticals
  • 02 Aug 2017 Discontinued - Phase-II for Muscular atrophy in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top